{
    "code": "60001158",
    "url": "https:\/\/info.fda.gov.tw\/MLMS\/H0001D.aspx?Type=Lic&LicId=60001158",
    "time": "2024-04-04 20:58:54",
    "許可證字號": "衛部菌疫輸字第001158號",
    "註銷狀態": "已註銷",
    "註銷日期": "113\/03\/26",
    "註銷理由": "自請註銷",
    "製造許可登錄編號": "",
    "有效日期": "115\/07\/27",
    "發證\/登錄日期": "110\/07\/27",
    "許可證\/登錄種類": "菌　疫",
    "舊證字號": "",
    "醫療器材級數": "",
    "第一等級醫療器材原許可證字號": "",
    "第一等級醫療器材新登錄字號": "",
    "通關簽審文件編號": "DHA06000115806",
    "中文品名": "適服瘤凍晶注射劑150毫克",
    "英文品名": "Samfenet 150 mg powder for concentrate for solution for infusion",
    "適應症": "應使用於下列HER2過度表現或HER2基因amplification之早期乳癌、轉移性乳癌病人：\r\n1.早期乳癌 (EBC)\r\n(1)經外科手術、化學療法(術前或術後)之輔助療法。\r\n(2)以doxorubicin與cyclophosphamide治療，再合併paclitaxel或docetaxel之輔助療法。\r\n(3)與docetaxel及carboplatin併用之輔助療。\r\n(4)術前與化學療法併用和術後之輔助療法使用於治療局部晚期(包括炎症)乳癌或腫瘤(直徑>2厘米)。\r\n2.轉移性乳癌(MBC)\r\n(1)單獨使用於曾接受過一次(含)以上化學療法之轉移性乳癌；除非病人不適合使用anthracycline或taxane，否則先前之化學治療應至少包括anthracycline或taxane。使用於荷爾蒙療法失敗之荷爾蒙受體陽性之病人，除非病人不適用荷爾蒙療法。\r\n(2)與paclitaxel或docetaxel併用於未曾接受過化學療法之轉移性乳癌。\r\n(3)與芳香環酶抑制劑併用於荷爾蒙受體陽性之轉移性乳癌。\r\n3.轉移性胃癌(MGC)\r\nSamfenet合併capecitabine (或5-fluorouracil)及cisplatin適用於未曾接受過化學治療之HER2過度表現轉移性胃腺癌(或胃食道接合處腺癌)的治療。",
    "劑型": "243凍晶注射劑",
    "包裝": "玻璃小瓶裝 100支以下盒裝",
    "儲存溫度": "",
    "有效期間": "",
    "指示藥品審查基準": "",
    "標籤、仿單及包裝加註": "",
    "藥品類別": "05限由醫師使用",
    "管制藥品分類級別": "",
    "藥品分類": "",
    "監視期限": "115\/07\/27",
    "主成分略述": "TRASTUZUMAB",
    "限制項目": "02輸　入 1D須執行風險管理計畫 91生物相似性藥品",
    "申請商名稱": "台灣三星國際醫藥有限公司",
    "申請商地址": "臺北市信義區忠孝東路4段560號13樓 (1305室)",
    "主製造廠": [
        {
            "製造廠名稱": "FAREVA PAU 2",
            "製造廠廠址": "50 CHEMIN DE MAZEROLLES, IDRON, 64320, FRANCE",
            "製造廠公司地址": "",
            "製造廠國別": "FRANCE",
            "製程": "成品製造廠"
        },
        {
            "製造廠名稱": "PATHEON ITALIA S.P.A.",
            "製造廠廠址": "2 TRAV. SX VIA MOROLENSE, 5-03013 FERENTINO (FR), ITALY",
            "製造廠公司地址": "",
            "製造廠國別": "ITALY",
            "製程": "成品製造廠"
        }
    ],
    "次製造廠": [
        {
            "製造廠名稱": "ENESTIA BELGIUM NV",
            "製造廠廠址": "KLOCKNERSTRAAT 1, HAMONT-ACHEL, B-3930, BELGIUM",
            "製造廠公司地址": "",
            "製造廠國別": "BELGIUM",
            "製程": "二級包裝廠"
        },
        {
            "製造廠名稱": "FARMACEUTICI FORMENTI S.P.A",
            "製造廠廠址": "VIA DI VITTORIO, 2, 21040 ORIGGIO (VA) ITALY",
            "製造廠公司地址": "VIA VITTOR PISANI 16,20124 MILANO, ITALY",
            "製造廠國別": "ITALY",
            "製程": "二級包裝廠"
        },
        {
            "製造廠名稱": "FUJIFILM DIOSYNTH BIOTECHNOLOGIES DENMARK APS",
            "製造廠廠址": "BIOTEK ALLE 1, HILLEROD, 3400, DENMARK",
            "製造廠公司地址": "",
            "製造廠國別": "DENMARK",
            "製程": "原料藥製造廠"
        },
        {
            "製造廠名稱": "Samsung Biologics Co. Ltd.",
            "製造廠廠址": "300 Songdo bio-daero, Yeonsu-gu, Incheon City, Korea 21987, Korea Republic",
            "製造廠公司地址": "",
            "製造廠國別": "KOREA",
            "製程": "原料藥製造廠"
        }
    ],
    "CCC號列": "",
    "藥理治療分類": "",
    "ingredients": [
        {
            "成分類別": "主成分",
            "成分代碼": "1013000500",
            "成分名稱": "TRASTUZUMAB",
            "含量描述": "",
            "含量": "150.0000000000",
            "單位": "MG"
        }
    ],
    "仿單外盒": [
        {
            "title": "附件2 SB3 TW leaflet mock-up v5.0-110-12-20.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=60001158&Seq=001&Type=9"
        },
        {
            "title": "SB3_TW_150mg_Label-110-12-20.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=60001158&Seq=002&Type=8"
        },
        {
            "title": "SB3_TW_150mg_Carton-110-12-20.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=60001158&Seq=001&Type=8"
        }
    ]
}